Table 3 Hazard ratios of use of statin and fibrate for risk of cardiovascular disease in Chinese type 2 diabetic patients
Exposures | HR | 95%CI | P value |
|---|---|---|---|
In the entire cohort§†|  |  |  |
Use of statins during follow-up | 0.66 | 0.50 to 0.88 | .0038 |
Use of fibrates during follow-up | 0.61 | 0.37 to 1.03 | .0640 |
In the sub-cohort with LDL-C < 3.0 mmol/L¶, § |  |  |  |
Use of statins during follow-up | 1.10 | 0.56 to 2.16 | .7798 |
Use of fibrates during follow-up | 0.34 | 0.12 to 1.00 | .0495 |
In the sub-cohort with LDL-C ≥ 3.0 mmol/L¶, § |  |  |  |
Use of statins during follow-up | 0.60 | 0.44 to 0.82 | .0012 |
Use of fibrates during follow-up | 0.65 | 0.35 to 1.19 | .1590 |
In the sub-cohort with HDL-C < 1.0 mmol/L in male or 1.3 mmol/L in female ζ, § |  |  |  |
Use of statins during follow-up | 0.49 | 0.28 to 0.88 | .0162 |
Use of fibrates during follow-up | 0.37 | 0.13 to 1.09 | .0703 |
In the sub-cohort with HDL-C ≥1.0 mmol/L in male or ≥ 1.3 mmol/L in female ζ, § |  |  |  |
Use of statins during follow-up | 0.73 | 0.53 to 1.02 | .0662 |
Use of fibrates during follow-up | 0.74 | 0.41 to 1.35 | .3303 |
In the sub-cohort with metabolic syndrome at baseline ‡,§ |  |  |  |
Use of statins during follow-up | 0.58 | 0.42 to 0.80 | .0010 |
Use of fibrates during follow-up | 0.60 | 0.35 to 1.05 | .0713 |
In the sub-cohort without metabolic syndrome at baseline ‡,§ |  |  |  |
Use of statins during follow-up | 0.77 | 0.42 to 1.44 | .4201 |
Use of fibrates during follow-up | 0.57 | 0.12 to 2.73 | .4903 |